Trelagliptin Succinate can delay the degradation of endogenous glucagon like peptide-1 (GLP-1), thereby increasing the plasma concentration of active GLP-1.

1、 Drug name

1. Common name: Tragliptin

2. Product Name: Zafatek Tablets

3. English name: Trelagliptin Succinate

4. Dosage form: Film coated tablets

2、 Indications

It is suitable for type 2 diabetes, and should be used when the blood sugar control is still not ideal on the basis of diet control and exercise therapy.

3、 Specifications and characteristics

1. Specification: 100mg/tablet (calculated as quercetin)

2. Appearance: 100mg: Light red double-sided scratch film, identification code D389, diameter about 11.0mm, thickness about 3.8mm.

4、 Main components

Each tablet contains the equivalent of 100mg of quercetin succinate

5、 Usage and dosage

Adults usually take 100mg orally once a week (calculated as trogliptin), and it is recommended to take it on a fixed date.

6、 Dose adjustment

Moderate or severe renal insufficiency patients need to adjust the dosage:

Moderate (Ccr30-50mL/min): dose reduced to 50mg/week

Severe (Ccr<30mL/min) or end-stage renal disease: dose reduced to 25mg/week.

7、 Medication precautions

1. Before and after meals: It is recommended to take it 30 minutes before breakfast as the food has a minimal impact on absorption.

2. Omission of medication: If you forget to take the medication, you should immediately take it when you remember, and then continue to take the medication according to the original date. Do not double the dosage.

3. Vomiting: If vomiting occurs after taking medication, it is not recommended to take it again and wait for the next scheduled medication time.

4. Other: Regular monitoring of blood sugar is necessary. If the effect is not satisfactory after 2-3 months, adjustments to the treatment plan should be considered.

8、 Medication for special populations

1. Renal insufficiency: The dosage needs to be adjusted according to the creatinine clearance rate.

2. Liver dysfunction: Patients with moderate liver dysfunction do not need to adjust the dosage.

3. Pregnant women: Use only when the benefits outweigh the risks.

4. Breastfeeding period: It is recommended to balance breastfeeding with the necessity of treatment.

5. Children: No clinical data available, not recommended for use.

6. Elderly people: Due to possible decline in kidney function, medication should be taken with caution and adverse reactions should be monitored.

9、 Adverse reactions

1. Common side effects (0.1-5%): rash, itching, atrial fibrillation, elevated liver function indicators, elevated amylase, nasopharyngitis, etc.

2. Serious side effects: Hypoglycemia (especially when combined with sulfonylureas or insulin), acute pancreatitis, intestinal obstruction, pemphigus vulgaris.

10、 Contraindications

The following patients are prohibited:

1. Severe ketosis, diabetes coma or type 1 diabetes;

2. Severe infection, perioperative period, severe trauma;

3. Individuals with a history of allergies to the ingredients of this product.

11、 Drug interactions

1. Combination use with sulfonylureas and insulin may increase the risk of hypoglycemia and should be considered for reduction;

2. β - blockers, salicylic acid preparations, etc. may enhance the hypoglycemic effect;

3. Adrenaline, corticosteroids, etc. may weaken the hypoglycemic effect.

12、 Storage method

Store at room temperature and avoid moisture and high temperatures.

Trelagliptininformation